Adial Pharmaceuticals Inc
NASDAQ:ADIL

Watchlist Manager
Adial Pharmaceuticals Inc Logo
Adial Pharmaceuticals Inc
NASDAQ:ADIL
Watchlist
Price: 0.306 USD -0.84% Market Closed
Market Cap: 7.3m USD

Profitability Summary

Adial Pharmaceuticals Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Adial Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-7.9m USD
Operating Income
-7.9m USD
Other Expenses
-197k USD
Net Income
-8.1m USD

Margins Comparison
Adial Pharmaceuticals Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Adial Pharmaceuticals Inc
NASDAQ:ADIL
7.3m USD N/A N/A
US
Eli Lilly and Co
NYSE:LLY
942.9B USD
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
488B USD
27%
27%
CH
Roche Holding AG
SIX:ROG
252.8B CHF
34%
15%
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
24%
16%
CH
Novartis AG
SIX:NOVN
206.2B CHF
33%
26%
US
Merck & Co Inc
NYSE:MRK
247.4B USD
38%
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
42%
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
11%
-126%
US
Pfizer Inc
NYSE:PFE
148.6B USD
29%
16%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Adial Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Adial Pharmaceuticals Inc
NASDAQ:ADIL
7.3m USD
-155%
-130%
-151%
-931%
US
Eli Lilly and Co
NYSE:LLY
942.9B USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
488B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
252.8B CHF
33%
10%
31%
19%
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
22%
9%
18%
15%
CH
Novartis AG
SIX:NOVN
206.2B CHF
33%
14%
25%
18%
US
Merck & Co Inc
NYSE:MRK
247.4B USD
40%
15%
26%
21%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
148.6B USD
11%
5%
11%
10%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less